Radiol Oncol 1992; 26: 223-7.

Serum TNF-α levels in melanoma-bearing and healthy mice

Breda Kus[1,3], Gregor Serša[2], Srdjan Novaković[2] and Anton Štalc[1]

[1] LEK Pharmaceutical and Chemical Company, d. d., Research and Development.
[2] Institute of Oncology, Department of Tumor Biology and Biotherapy, Ljubljana.
[3] Institute of Chemistry, Ljubljana.

To determine differences in tumor necrosis factor-α (TNF-α) persistency after TNF-α therapy, serum levels were monitored in tumor bearing and healthy mice. Melanoma B-16-bearing mice were treated peritumorally and healthy mice subcutaneously with recombinant human TNF-α, lacking 1-3 amino acids from N-terminal part (TNF-αNv3). In healthy mice the peak TNF-α serum levels were detected one hour after application, while in tumor-bearing mice two hours after application. Also TNF-α elimination from serum of tumor-bearing mice was slower compared to healthy mice. The data suggest that TNF-αNv3 pharmacokinetic mechanisms in tumor-bearing and healthy mice are different.

Key words: tumor necrosis factor; pharmacokinetics; melanoma, experimental; mice

Introduction

Tumor necrosis factor-α (TNF-α) is a monocyte/macrophage derived protein, originally identified by its ability to induce haemorrhagic necrosis of some tumors *in vivo*[1] and cytotoxicity against certain tumor cells *in vitro*.[2] The results of clinical trials with recombinant human TNF-α indicate that the side effects of TNF-α treatment can be severe.[3,4] For rational dose regimen, which could diminish the side effects, it is important to know how TNF-α is absorbed from the site of application, distributed through the body, and its activity preserved.

Correspondence to: Breda Kus MSc, LEK Pharmaceutical and Chemical Company, d. d., Research and Development, 61007 Ljubljana, Celovška 135, Slovenia.

UDC: 616-066, 81-085-092,9

Despite the fact that TNF-α activity is at least partially species specific, animal models were often used to study pharmacokinetics of human TNF-α. However in all previous pharmacokinetic studies in mice,[5] rats,[6,7] rabbits and monkeys,[8] human recombinant TNF-α was applied to healthy animals.

Therefore the aim of our study was to compare absorption and distribution of human TNF-α in tumor-bearing and healthy mice. Besides antitumor effect, serum TNF-α levels were measured after local TNF-α application. Human recombinant TNF-α, lacking 1-3 amino acids from N-terminal part (TNF-αNv3), was applied peritumorally in melanoma B-16 bearing mice and subcutaneously in healthy mice.

Materials and methods

Animals

Inbred C57Bl/6 mice were purchased from Rudjer Bošković Institute, Zagreb, Croatia. Animals were maintained in constant room temperature (24^0C) at a natural day/night cycle in a conventional mouse colony. Mice in good condition, without signs of fungal or other infections, 8-10 weeks old, were used in the experiments.

Tumors

Melanoma B-16 was maintained in C57Bl/6 mice by serial transplantation. Tumor cells from the fourth isotransplantat generation were prepared for the described experiments by gentle mechanical disagregation. Solid subcutaneous tumors, dorsolaterally in animals, were initiated by injection of 5×10^5 viable melanoma cells. The viability of the cells was determined by trypan blue dye exclusion test.[9]

Tumor necrosis factor

Recombinant human tumor necrosis factor-α analog, lacking 1-3 amino acids from N-terminal end (TNF-αNv3), was used (ZIMET, Jena, Germany). Specific activity was 2.2×10^7 U/mg, tested on L929 cells in the presence of actinomycin-D. Other properties of TNF-αNv3 were described before.[10] TNF-αNv3 was diluted in PBS (pH 7.4) before use.

Treatment

TNF-αNv3 was administered subcutaneously in tumor free and peritumorally in tumor-bearing mice.[9] The treatment was started when the tumors reached 30-40 mm^3 in volume. TNF-αNv3 application dose was 2 x 10^5 U per animal, which gave 9 x $10^3 \pm 1039$ U/g of animal.

Tumor measurement

Tumor growth was followed by measuring three mutually orthogonal tumor diameters with a Vernier calliper. Tumor volumes were calculated by formula $\pi/6 \cdot a \cdot b \cdot c$ (a, b, c are tumor diameters). From the measurements, arithmetic means (AM) and standard errors of the means (SE) were calculated for each experimental group with minimum of 10 mice. Growth delay of the tumors was calculated from individual tumor growth, by determining the time required for tumor to reach 150 mm^3 of volume, and subtracting the relevant time in the control group.[9,11]

Blood sample collection and handling

One day before TNF-αNv3 application blood was collected from all animals in the experiment for monitoring the serum TNF-α level. After the application of TNF-αNv3 blood samples were taken from four animals at the times indicated in the figures. Blood was collected from the orbital sinus of the animals, immediately centrifuged (3000 rpm/min) for 10 min at 4° C and sterilised by filtration (0.22 μm cellulose acetate filter, Costar). Samples were stored at -70° C for TNF-α assay.

Cells and culture conditions

L929 murine transformed fibroblasts were obtained from Istituto Zooprofilattico Sperimentale, Brescia, Italy. Cells were cultured in Eagle's minimal essential medium (EMEM) with 10% fetal calf serum (FCS). Incubation was carried out at 37° C in a humidified 5% CO_2 incubator.

Determination of TNF-α serum concentrations

a) L929 bioassay. Cytotoxicity of TNF-α was determined on L929 cells[12] in the presence of actinomycin D. The viable cells density was determined 20 h after TNF-αNv3 treatment.

Culture medium was removed and the cells, fixed with glutaraldehyde, were stained with crystal violet (0.5 % in 20 % methanol). Bound dye was eluted with 0.1 ml of 1% sodium dodecyl sulfate. The optical density was measured at 540 nm using microplate photometer CLS962 (Cambridge Life Sciences plc). Cytotoxic activity expressed as TNF-α U/ml was defined as the reciprocal of the dilution which gives 50% cell killing. The detection limit of the assay was 40 U/ml of serum. Cytotoxic activity for one sample was calculated as AM of six independent measurements. AM of three TNF-αNv3 activities in sera prepared from three mice in test group, are presented in figures.

b) TNF-α ELISA. Immunologically active TNF-α was determined by a "sandwich" enzyme immunosorbent assay (ELISA) specific for human TNF-α (Du Pont). The detection limit was 100 pg/ml of serum. TNF-αNv3 value for one sample was calculated as AM of two independent measurements. AM of three TNF-αNv3 values in sera prepared from three mice in test group, are presented in the results.

Statistical evaluation

The results were evaluated by Student's unpaired probability test and correlation coefficient. All statistical procedures were computed using CSS Programme Stat Soft. Levels of less than 0.05 were taken as indicating significant differences.

Results

Antitumor effect of TNF-αNv3

Melanoma B-16-bearing mice were treated peritumorally with 2 x 10^5 U TNF-αNv3, when tumors reached average tumor volume 34.4 ± 3.9 mm^3. Tumor growth delay after TNF-αNv3 treatment (3.8 ± 0.4 days) was significant ($P < 0.05$), compared to tumor growth in control animals, which were treated with physiological saline (Figure 1). No side effects were observed after peritumoral treatment with TNF-αNv3.



Figure 1. Antitumor effect of TNF-αNv3 on subcutaneous melanoma B-16 after peritumoral (●) treatment with TNF-αNv3 (2 x 10^5 U/mouse); controls (▲).

Endogenous TNF-α levels in mice before application of TNF-αNv3

Endogenous serum TNF-α levels were measured with L929-cell assay method, in sera collected one day before the TNF-αNv3 application from tumor-bearing and healthy animals. In all serum samples tested (15 from healthy and 24 from tumor bearing animals), endogenous TNF-α levels were below the reliable detection limit (40 U/ml) of the method.

The same serum samples were tested also on ELISA to test the method for possible interference of other immunological substances. Results were negative for all serum samples. This confirms that no component in the murine serum, prepared as described, interferes with our ELISA assay system.

Serum levels of TNF-αNv3 after peritumoral application

Serum TNF-α concentrations in B-16-melanoma bearing mice were compared to concentrations of TNF-α in healthy mice without tumors. Tumor-bearing mice were treated peritu-



Figure 2. Mean ± SE serum levels time curves of cytotoxically active TNF-αNv3 after peritumoral application (2 x 10^5 U/mouse) in B-16-bearing (▲) and healthy mice (●).



Figure 3. Mean ± SE serum levels time curves of TNF-αNv3 antigen after peritumoral application (2 x 10^5 U/mouse) in B-16-bearing (▲) and healthy mice (●).

morally, while healthy mice subcutaneously with 2 x 10^5 U TNF-αNv3. In the same serum samples, TNF-α cytotoxic activity (Figure 2) and immunologically active TNF-α molecules (Figure 3) were determined. Delayed TNF-α serum peak levels were observed in tumor-bearing mice (120 min.) compared to healthy mice (60 min.). Also, TNF-α serum concentrations were higher in tumor-bearing mice. The highest TNF-α serum level in tumor-bearing mice was 3.6 x 10^3 U/ml (L929 assay) or 8 x 10^4 pg/ml (ELISA), and 1.6 x 10^3 U/ml or 6 x 10^3 pg/ml in healthy mice ($P < 0.05$ in both assays). High TNF-α serum levels persisted in tumor-bearing animals, compared to quick clearance from healthy mice. Ten hours after TNF-αNv3 application its level in tumor bearing animals was 2.8 x 10^2 U/ml or 7 x 10^3 pg/ml, while in healthy mice already after four hours dropped to 83 U/ml or 1 x 10^2 pg/ml.

Discussion

The *in vivo* antitumor effects of murine TNF-α[13] and human TNF-α[14] have been reported on different murine tumors transplanted in syngenic mice. In our previous study antitumor effects of TNF-α analog TNF-αNv3 after peritumoral application was established on SA1 sarcoma and B-16 melanoma tumors.[9,11] In this study the potent antitiumor effect of TNF-αNv3 is reconfirmed on B-16 melanoma tumors.

The results of TNF-α serum level measurement show that TNF-αNv3 pharmacokinetic mechanisms in tumor-bearing and healthy mice are different. TNF-α concentration-time profiles, presented in Figures 2 and 3 indicate, that TNF-α in serum of B-16-bearing mice persists longer than in serum of healthy mice.

TNF-αNv3 was measured in sera cytotoxically and immunologically in tumor-bearing and healthy mice after peritumoral or subcutaneous application, respectively. Relationship between results obtained by the two assays shows almost perfect positive correlation ($R = 0.88$ for healthy and $R = 0.98$ for tumor-bearing mice). Besides, it was established that no component from sera interfered with ELISA assay used. Although TNF-α levels were often found to be increased in sera of cancer patients[15] we didn't detect endogenous TNF-α before TNF-αNv3

application neither in sera from healthy nor in sera from tumor-bearing mice. Therefore we believe that all TNF-α activity detected in serum originates from TNF-αNv3 applied.

The influence of B-16 tumor on the persistence of TNF-α activity in serum is documented for the first time. If other tumors also affect the persistence of TNF-α serum concentration in a similar way, the pharmacokinetic parameters from healthy animals can not be extrapolated to tumor-bearing animals; consequently for the prediction of human therapy only pharmacokinetic data obtained by tumor-bearing animal models can be used.

In conclusion, this study demonstrates that peritumoral treatment with TNF-α analog, lacking first three amino acids from N- terminal part, has antitumor effect on B-16 tumors. Comparison of TNF-α serum concentration-time profiles in tumor-bearing and healthy mice, indicate that the absorption, distribution and/or metabolism of TNF-Nv3 in B-16 tumor-bearing mice are significantly different from those in healthy mice. The mechanism for mentioned differences between tumor-bearing and healthy mice remains to be clarified in further studies.

Acknowledgement

The financial support by grant A185 of the Ministry for Science and Technology of Slovenia is gratefully acknowledged.

References

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci USA* 1975; **72**: 3666-70.
2. Helson L, Green S, Carswell EA, Old LJ. Effect on tumor necrosis factor on cultured human melanoma cells. *Nature* 1975; **258**: 731-2.
3. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. *Cancer Res* 1987; **47**: 2986-9.
4. Kramer SM, Sherwin SA. Tumor necrosis factor: drug development perspective. *Drug News Perspect* 1989; **2**: 214-7.
5. Noguchi K, Inagawa H, Tsuji Y, Morikawa A, Mizuno DI, Soma GI. Antitumor activity of a novel chimera tumor necrosis factor (TNF- STH) constructed by connecting rTNF-S with thymosin against murine syngenic tumors. *J Immunother* 1991; **10**: 105-11.
6. ZahnG, Greischel A. Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats. *Drug Res* 1989; **39**: 1180-2.
7. Ferraiolo BL, McCabe J, Hollenbach S, Hultgren B, Pitti R, Wilking H. Pharmacokinetics of recombinant human tumor necrosis factor-α in rats. *Drug Methab Dispos* 1989; **17**: 369-72.
8. Bocci V, Paccini A, Pessina P, Maioli E, Naldini A. Studies on tumor necrosis factor (TNF) I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration. *Gen Pharmacol* 1987; **18**: 343-6.
9. Serša G, Novaković S, Štalc A. Tumor mass is a critical factor in peritumoral treatment with tumor necrosis factor. *Period Biol* 1992; **94**: 35-40.
10. Kus B, Štalc A. Biological activities of a derivative of human tumor necrosis factor-α lacking three N-terminal amino acids. *Acta Pharm* 1992; **42**: 117-24.
11. Serša G, Novaković S, Štalc A. Antitumor effect of recombinant human tumor necrosis factor-α analog combined with desmuramyl dipeptides LK-409 or LK-410 on sarcoma in mice. *Mol Biother* 1992; **4**: in press.
12. Matthews N, Neale ML. Cytotoxicity assays for tumor necrosis factor and lymphotoxin. In: Clemens MJ, Morris AG, Gearing AJH eds. *Lymphokines and Interferones* Oxford: IRL Press, 1987: 221-5.
13. Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and hetero-transplanted human tumors in nude mice. *Int J Cancer* 1984; **34**: 263-7.
14. Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y, Furuichi H. Recombinant human tumor necrosis factor - II. Antitumor effects on murine and human tumors transplanted in mice. *Int J Immunopharmac* 1986; **8**: 357-68.
15. Aderka D, Fisher S, Levo Y, Holtman H, Hahn T, Wallach D. Cachectin/tumor necrosis factor production by cancer patients. *Lancet* 1985; **2**: 1190.